Company profile: Chembio Diagnostics
1.1 - Company Overview
Company description
- Provider of proprietary rapid point-of-care diagnostic tests, developing, manufacturing, licensing and marketing DPP assays for HIV 1/2, HIV-Syphilis, Zika (IgM/IgG in Europe; IgM in the USA), Ebola antigen (USA), and Zika-Chikungunya-Dengue (Europe). Portfolio includes two FDA PMA-approved, CLIA-waived rapid HIV tests marketed in the U.S. by Alere (formerly Inverness Medical Innovations).
Products and services
- DPP® HIV-Syphilis Assay: Multiplex, rapid point-of-care test that simultaneously detects antibodies to HIV and Syphilis for combined serological screening
- DPP® HIV 1/2 Assay: Point-of-care, rapid test detecting antibodies to HIV‑1 and HIV‑2 from oral fluid, fingerstick blood, venous whole blood, serum, and plasma across multiple specimen formats
- DPP® ZCD IgM/IgG System: IgM/IgG-format diagnostic system that detects antibodies to Zika, Chikungunya, and Dengue viruses in Europe for comprehensive tri-pathogen serological assessment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Chembio Diagnostics
Vaxcyte
HQ: United States
Website
- Description: Provider of vaccines and vaccine development technologies, including VAX-24, a 24-valent pneumococcal conjugate vaccine for preventing invasive pneumococcal disease in adults (FDA Breakthrough Therapy); VAX-31, a 31-valent pneumococcal conjugate candidate; the XpressCF cell-free platform for site-specific conjugation to enhance immunogenicity; and preclinical programs for Group A Strep, periodontitis, and Shigella.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxcyte company profile →
Meretek Diagnostics
HQ: United States
Website
- Description: Provider of non-invasive, non-radioactive breath tests and instruments for diagnostic applications, offering BreathTek UBT and BreathTek-UBiT collection kits for qualitative detection of urease associated with Helicobacter pylori in the human stomach, supporting initial diagnosis and post-treatment monitoring of Helicobacter pylori infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Meretek Diagnostics company profile →
Taxis Pharmaceuticals
HQ: United States
Website
- Description: Provider of anti-infective pharmaceuticals focused on discovery and development of novel agents, including TXA709, an oral anti-MRSA agent targeting the FtsZ bacterial cell division protein (completed Phase I), and efflux pump inhibitors for Gram-negative MDR pathogens by inhibiting resistance efflux pumps.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Taxis Pharmaceuticals company profile →
Generate:Biomedicines
HQ: United States
Website
- Description: Provider of a machine learning-powered platform to create new drugs on demand across biologic modalities, accelerating therapeutic identification and validation; Chroma, an open-source AI model that programs novel proteins with targeted properties; and a clinical pipeline (GB-0895 for asthma, GB-0669 targeting SARS-CoV-2), with an expanded collaboration with Amgen to develop novel proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Generate:Biomedicines company profile →
Friz Biochem
HQ: Germany
Website
- Description: Provider of advanced electronic biochips and offerings integrating the complete workflow of molecular diagnostics; privately held, founded in October 2004 and based in Neuried near Munich.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Friz Biochem company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Chembio Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Chembio Diagnostics
2.2 - Growth funds investing in similar companies to Chembio Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Chembio Diagnostics
4.2 - Public trading comparable groups for Chembio Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →